Back to top
more

SCYNEXIS (SCYX)

(Delayed Data from NSDQ)

$1.47 USD

1.47
120,233

-0.03 (-2.00%)

Updated Apr 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

by Zacks Equity Research

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of 3,000% and 16.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avalo Therapeutics, Inc. (AVTX) delivered earnings and revenue surprises of 34.44% and 35.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

by Zacks Equity Research

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Lags Q3 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of -47.89% and 53.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will SCYNEXIS Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

Scynexis (SCYX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Scynexis (SCYX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to SCYNEXIS (SCYX) stock based on the movements in the options market lately.

Scynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 11.11% and -5.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of -20.00% and -24.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Scynexis (SCYX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Scynexis (SCYX) delivered earnings and revenue surprises of 30.00% and 6.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?